Optimizing the management of benign prostatic hyperplasia

Dean S. Elterman, Jack Barkin, Steven A. Kaplan

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


One of the challenges facing primary care physicians and specialists as the population ages is the management of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). While as many as 18% of men in their 40s report bother from an enlarged prostate, that figure rises dramatically, whereby 50% of men in their 50s and 90% of men in their 90s will complain of bothersome symptoms related to an enlarged prostate. Studies have shown that BPH is a progressive disease, which if left untreated can result in worsening of symptoms, acute urinary retention and renal failure. Until about 20 years ago the only management option available to urologists was surgery. In the early 1990s medical therapy emerged as the predominant treatment for BPH. Therapy may be tailored to target symptoms and progression of disease.

Original languageEnglish
Pages (from-to)77-83
Number of pages7
JournalTherapeutic Advances in Urology
Issue number2
StatePublished - Apr 2012
Externally publishedYes


  • 5-alpha-reducinhibitors
  • LUTS
  • alpha-blockers
  • anticholinergics
  • benign prostatic hyperplasia


Dive into the research topics of 'Optimizing the management of benign prostatic hyperplasia'. Together they form a unique fingerprint.

Cite this